CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other EventsItem 8.01. Other Events
On July 25, 2017, CRISPR Therapeutics AG (the “Company”) issued a press release entitled “CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
|
ExhibitNo. |
Description |
| 99.1 | Press Release by CRISPR Therapeutics AG, dated July 25, 2017 |
CRISPR Therapeutics AG ExhibitEX-99.1 2 d417513dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CONFIDENTIAL CLIA DRAFT FOR PLANNED RELEASE TUESDAY 25-JULY AT 4:30 PM EASTERN TIME CRISPR Therapeutics,…To view the full exhibit click here
About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.